Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer



Status:Completed
Conditions:Breast Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:August 2011
End Date:July 2014

Use our guide to learn which trials are right for you!

A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer

This is a Phase 2, multicenter, single-arm, feasibility study evaluating eribulin in
combination with capecitabine as an adjuvant chemotherapy regimen in approximately 65
subjects with early-stage (I-II), human epidermal growth factor receptor 2 (HER2)- normal,
estrogen receptor (ER)-positive breast cancer.


Inclusion Criteria:

1. Male subjects aged greater than or equal to 18 years and female subjects who must be
postmenopausal (at least 12 months consecutive amenorrheic or have had a bilateral
oophorectomy or, if they have had a hysterectomy but with ovaries intact, then
females must be age 55 or older and with postmenopausal follicle-stimulating hormone
[FSH] levels).

2. Subject is a candidate for chemotherapy in the adjuvant setting.

- Adjuvant therapy must begin within 84 days of the final surgical procedure for
breast cancer.

3. Histologically confirmed Stage I to II invasive breast cancer. Subjects may have more
than one synchronous primary breast tumor.

4. Receptor Status:

- HER2-normal as determined by a negative fluorescence in situ hybridization
(FISH) result or 0 to 1+ by immunohistochemistry (IHC) staining result

- ER-positive, node-negative or ER-positive Grade 1 or 2 node-positive breast
cancer

5. ECOG performance status of 0 or 1

6. Adequate renal function as evidenced by serum creatinine less than or equal to 1.5
mg/dL or calculated creatinine clearance greater than or equal to 50 mL/min per the
Cockcroft and Gault formula

7. Adequate bone marrow function as evidenced by ANC greater than or equal to 1.5 x
10^9/L, hemoglobin greater than or equal to 10.0 g/dL, and platelet count greater
than or equal to 100 x 10^9/L

8. Adequate liver function as evidenced by bilirubin less than or equal to 1.5 times the
upper limits of normal (ULN) and alkaline phosphatase, alanine aminotransferase
(ALT), and aspartate aminotransferase (AST) less than or equal to 3 x ULN

9. Male subjects must have had a successful vasectomy (confirmed azoospermia), or their
female partners must not be of childbearing potential, or male subjects must agree to
use and have their female partners use a highly effective method of contraception
(e.g., total abstinence, an intrauterine device, a double-barrier method [such as
condom plus diaphragm with spermicide] throughout the entire study period and for 30
days after study drug discontinuation..

10. Voluntary agreement to provide written informed consent and willingness and ability
to comply with all aspects of the protocol

Exclusion Criteria:

1. Stage III and IV invasive breast cancer

2. Prior chemotherapy, radiation therapy, immunotherapy or biotherapy for current breast
cancer

3. Nonmalignant systemic disease (cardiovascular, renal, hepatic, etc) that would
preclude any of the study therapy drugs

4. Subjects with a concurrently active second malignancy other than adequately treated
nonmelanoma skin cancers or in situ cervical cancer

5. Subjects with pre-existing neuropathy greater than Grade 2

6. Subjects with known positive human immunodeficiency virus (HIV) status

7. Females of childbearing potential. Females will be considered to be of childbearing
potential unless they are postmenopausal (at least 12 months consecutive amenorrheic
or have had a bilateral oophorectomy or, if they have had a hysterectomy but with
ovaries intact, then females must be age 55 or older and with postmenopausal FSH
levels).

8. Subjects with current gastrointestinal disease or other condition resulting in an
inability to take or absorb oral medications

9. Subjects with known allergy or hypersensitivity to eribulin mesylate or its
excipients, or to fluoropyrimidine therapy (with or without documented
dihydropyrimidine dehydrogenase [DPD] deficiency)

10. A clinically significant electrocardiogram (ECG) abnormality, including a marked
baseline prolongation of QT/QTc interval (time between the start of the Q wave and
the end of the T wave/QT interval corrected for heart rate) (e.g., repeated
demonstration of a QTc interval greater than 500 ms)

11. Any medical or other condition which, in the opinion of the investigator, would
preclude participation in a clinical trial
We found this trial at
23
sites
?
mi
from
Bronx, NY
Click here to add this to my saved trials
Albany, New York 12206
?
mi
from
Albany, NY
Click here to add this to my saved trials
Austin, Texas 78731
?
mi
from
Austin, TX
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Denton, Texas 76210
?
mi
from
Denton, TX
Click here to add this to my saved trials
Fort Worth, Texas 76104
?
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Greenville, South Carolina 29605
?
mi
from
Greenville, SC
Click here to add this to my saved trials
Houston, Texas 77024
?
mi
from
Houston, TX
Click here to add this to my saved trials
Lewisville, Texas 75067
?
mi
from
Lewisville, TX
Click here to add this to my saved trials
Marietta, Georgia 30060
?
mi
from
Marietta, GA
Click here to add this to my saved trials
5900 Lake Wright Dr
Norfolk, Virginia 23502
(757) 466-8683
Virginia Oncology Associates Virginia Oncology Associates is an oncology and hematology practice of physicians, specializing...
?
mi
from
Norfolk, VA
Click here to add this to my saved trials
Orlando, Florida 32806
?
mi
from
Orlando, FL
Click here to add this to my saved trials
Paris, Texas 75460
?
mi
from
Paris, TX
Click here to add this to my saved trials
100 NE Loop 410; Suite 600
San Antonio, Texas 78216
210-424-1600
Cancer Care Centers of South Texas At Cancer Care Centers of South Texas, we are...
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
Spokane, Washington 99218
?
mi
from
Spokane, WA
Click here to add this to my saved trials
?
mi
from
Tucson, AZ
Click here to add this to my saved trials
Tucson, Arizona 85715
?
mi
from
Tucson, AZ
Click here to add this to my saved trials
Tyler, Texas 75702
?
mi
from
Tyler, TX
Click here to add this to my saved trials
Vancouver, Washington 98684
?
mi
from
Vancouver, WA
Click here to add this to my saved trials
2811 Tieton Drive
Yakima, Washington 98902
?
mi
from
Yakima, WA
Click here to add this to my saved trials